These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 30917125)

  • 1. First-in-human Phase I studies of PRS-080#22, a hepcidin antagonist, in healthy volunteers and patients with chronic kidney disease undergoing hemodialysis.
    Renders L; Budde K; Rosenberger C; van Swelm R; Swinkels D; Dellanna F; Feuerer W; Wen M; Erley C; Bader B; Sommerer C; Schaier M; Meurer K; Matis L
    PLoS One; 2019; 14(3):e0212023. PubMed ID: 30917125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of Ferric Pyrophosphate Citrate, a Novel Iron Salt, Administered Intravenously to Healthy Volunteers.
    Pratt RD; Swinkels DW; Ikizler TA; Gupta A
    J Clin Pharmacol; 2017 Mar; 57(3):312-320. PubMed ID: 27557937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-in-human phase I study of PRS-050 (Angiocal), an Anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumors.
    Mross K; Richly H; Fischer R; Scharr D; Büchert M; Stern A; Gille H; Audoly LP; Scheulen ME
    PLoS One; 2013; 8(12):e83232. PubMed ID: 24349470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
    Smith WB; Dowell JA; Pratt RD
    Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease.
    Sheetz M; Barrington P; Callies S; Berg PH; McColm J; Marbury T; Decker B; Dyas GL; Truhlar SME; Benschop R; Leung D; Berg J; Witcher DR
    Br J Clin Pharmacol; 2019 May; 85(5):935-948. PubMed ID: 30677788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained plasma hepcidin suppression and iron elevation by Anticalin-derived hepcidin antagonist in cynomolgus monkey.
    Hohlbaum AM; Gille H; Trentmann S; Kolodziejczyk M; Rattenstetter B; Laarakkers CM; Katzmann G; Christian HJ; Andersen N; Allersdorfer A; Olwill SA; Meibohm B; Audoly LP; Swinkels DW; van Swelm RPL
    Br J Pharmacol; 2018 Apr; 175(7):1054-1065. PubMed ID: 29329501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepcidin Response to Iron Therapy in Patients with Non-Dialysis Dependent CKD: An Analysis of the FIND-CKD Trial.
    Gaillard CA; Bock AH; Carrera F; Eckardt KU; Van Wyck DB; Bansal SS; Cronin M; Meier Y; Larroque S; Roger SD; Macdougall IC
    PLoS One; 2016; 11(6):e0157063. PubMed ID: 27276035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
    Brigandi RA; Johnson B; Oei C; Westerman M; Olbina G; de Zoysa J; Roger SD; Sahay M; Cross N; McMahon L; Guptha V; Smolyarchuk EA; Singh N; Russ SF; Kumar S;
    Am J Kidney Dis; 2016 Jun; 67(6):861-71. PubMed ID: 26827289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, pharmacokinetics and pharmacodynamics of the anti-hepcidin Spiegelmer lexaptepid pegol in healthy subjects.
    Boyce M; Warrington S; Cortezi B; Zöllner S; Vauléon S; Swinkels DW; Summo L; Schwoebel F; Riecke K
    Br J Pharmacol; 2016 May; 173(10):1580-8. PubMed ID: 26773325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
    Geisser P; Banké-Bochita J
    Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepcidin and diabetes are independently related with soluble transferrin receptor levels in chronic dialysis patients.
    Belo L; Rocha S; Valente MJ; Coimbra S; Catarino C; Bronze-da-Rocha E; Rocha-Pereira P; do Sameiro-Faria M; Oliveira JG; Madureira J; Fernandes JC; Miranda V; Santos-Silva A
    Ren Fail; 2019 Nov; 41(1):662-672. PubMed ID: 31296086
    [No Abstract]   [Full Text] [Related]  

  • 12. Two Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Studies To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza A Virus Monoclonal Antibody, MHAA4549A, in Healthy Volunteers.
    Lim JJ; Deng R; Derby MA; Larouche R; Horn P; Anderson M; Maia M; Carrier S; Pelletier I; Burgess T; Kulkarni P; Newton E; Tavel JA
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5437-44. PubMed ID: 27381392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease.
    Martin ER; Smith MT; Maroni BJ; Zuraw QC; deGoma EM
    Am J Nephrol; 2017; 45(5):380-388. PubMed ID: 28343225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and Safety of Ferric Pyrophosphate Citrate in Chinese Subjects with and without Hemodialysis-Dependent Stage 5 Chronic Kidney Disease.
    Gan L; Xie P; Tan Y; Wei G; Yuan X; Lu Z; Pratt R; Zhou Y; Hui AM; Li K; Fang Y; Zuo L
    Drugs R D; 2022 Jun; 22(2):119-129. PubMed ID: 35380419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of calcitriol on serum hepcidin in individuals with chronic kidney disease: a randomized controlled trial.
    Panwar B; McCann D; Olbina G; Westerman M; Gutiérrez OM
    BMC Nephrol; 2018 Feb; 19(1):35. PubMed ID: 29426300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
    Vaughan D; Speed J; Medve R; Andrews JS
    Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepcidin and proinflammatory markers in children with chronic kidney disease: A case-control study
.
    Goyal KK; Saha A; Sahi PK; Kaur M; Dubey NK; Goyal P; Upadhayay AD
    Clin Nephrol; 2018 May; 89(5):363-370. PubMed ID: 29451472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between serum hepcidin-25 and primary resistance to erythropoiesis-stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial.
    Gummer J; Trengove R; Pascoe EM; Badve SV; Cass A; Clarke P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM; Johnson DW; Olynyk JK; Ferrari P;
    Nephrology (Carlton); 2017 Jul; 22(7):548-554. PubMed ID: 27171136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum Hepcidin and Iron Indices Affect Anemia Status Differently According to the Kidney Function of Non-Dialysis Chronic Kidney Disease Patients: Korean Cohort Study For Outcome in Patients with Chronic Kidney Disease (KNOW-CKD).
    Lee SW; Kim YH; Chung W; Park SK; Chae DW; Ahn C; Kim YS; Sung SA
    Kidney Blood Press Res; 2017; 42(6):1183-1192. PubMed ID: 29227972
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.